Cargando…
High dose vitamin D supplementation does not affect biochemical bone markers in multiple sclerosis – a randomized controlled trial
BACKGROUND: People with multiple sclerosis have high risk of osteoporosis and fractures. A poor vitamin D status is a risk factor for MS, and vitamin D supplementation has been recommended both to prevent MS progression and to maintain bone health. METHODS: We assessed the effect of 20,000 IU vitami...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5381015/ https://www.ncbi.nlm.nih.gov/pubmed/28376767 http://dx.doi.org/10.1186/s12883-017-0851-0 |
_version_ | 1782519852693454848 |
---|---|
author | Holmøy, Trygve Lindstrøm, Jonas Christoffer Eriksen, Erik Fink Steffensen, Linn Hofsøy Kampman, Margitta T. |
author_facet | Holmøy, Trygve Lindstrøm, Jonas Christoffer Eriksen, Erik Fink Steffensen, Linn Hofsøy Kampman, Margitta T. |
author_sort | Holmøy, Trygve |
collection | PubMed |
description | BACKGROUND: People with multiple sclerosis have high risk of osteoporosis and fractures. A poor vitamin D status is a risk factor for MS, and vitamin D supplementation has been recommended both to prevent MS progression and to maintain bone health. METHODS: We assessed the effect of 20,000 IU vitamin D(3) weekly compared to placebo on biochemical markers of bone metabolism in 68 persons with relapsing remitting multiple sclerosis. RESULTS: Serum levels of 25-hydroxyvitamin D more than doubled in the vitamin D group, and parathyroid hormone decreased in the vitamin D group compared to the placebo group at week 48 and week 96. There was however no effect on bone formation as measured by procollagen type I N propeptide (PINP), or on bone resorption as measured by C-terminal cross-linking telopeptide of type I collagen (CTX1). Neither PINP nor CTX1 predicted bone loss from baseline to week 96. CONCLUSIONS: These findings corroborate the previously reported lack of effect of weekly high dose vitamin D supplementation on bone mass density in the same patients, and suggest that such vitamin D supplementation does not prevent bone loss in persons with MS who are not vitamin D deficient. TRIAL REGISTRATION: The trial was registered at ClinicalTrials.gov on April 4 2008, registration number NCT00785473. |
format | Online Article Text |
id | pubmed-5381015 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-53810152017-04-10 High dose vitamin D supplementation does not affect biochemical bone markers in multiple sclerosis – a randomized controlled trial Holmøy, Trygve Lindstrøm, Jonas Christoffer Eriksen, Erik Fink Steffensen, Linn Hofsøy Kampman, Margitta T. BMC Neurol Research Article BACKGROUND: People with multiple sclerosis have high risk of osteoporosis and fractures. A poor vitamin D status is a risk factor for MS, and vitamin D supplementation has been recommended both to prevent MS progression and to maintain bone health. METHODS: We assessed the effect of 20,000 IU vitamin D(3) weekly compared to placebo on biochemical markers of bone metabolism in 68 persons with relapsing remitting multiple sclerosis. RESULTS: Serum levels of 25-hydroxyvitamin D more than doubled in the vitamin D group, and parathyroid hormone decreased in the vitamin D group compared to the placebo group at week 48 and week 96. There was however no effect on bone formation as measured by procollagen type I N propeptide (PINP), or on bone resorption as measured by C-terminal cross-linking telopeptide of type I collagen (CTX1). Neither PINP nor CTX1 predicted bone loss from baseline to week 96. CONCLUSIONS: These findings corroborate the previously reported lack of effect of weekly high dose vitamin D supplementation on bone mass density in the same patients, and suggest that such vitamin D supplementation does not prevent bone loss in persons with MS who are not vitamin D deficient. TRIAL REGISTRATION: The trial was registered at ClinicalTrials.gov on April 4 2008, registration number NCT00785473. BioMed Central 2017-04-04 /pmc/articles/PMC5381015/ /pubmed/28376767 http://dx.doi.org/10.1186/s12883-017-0851-0 Text en © The Author(s). 2017 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Article Holmøy, Trygve Lindstrøm, Jonas Christoffer Eriksen, Erik Fink Steffensen, Linn Hofsøy Kampman, Margitta T. High dose vitamin D supplementation does not affect biochemical bone markers in multiple sclerosis – a randomized controlled trial |
title | High dose vitamin D supplementation does not affect biochemical bone markers in multiple sclerosis – a randomized controlled trial |
title_full | High dose vitamin D supplementation does not affect biochemical bone markers in multiple sclerosis – a randomized controlled trial |
title_fullStr | High dose vitamin D supplementation does not affect biochemical bone markers in multiple sclerosis – a randomized controlled trial |
title_full_unstemmed | High dose vitamin D supplementation does not affect biochemical bone markers in multiple sclerosis – a randomized controlled trial |
title_short | High dose vitamin D supplementation does not affect biochemical bone markers in multiple sclerosis – a randomized controlled trial |
title_sort | high dose vitamin d supplementation does not affect biochemical bone markers in multiple sclerosis – a randomized controlled trial |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5381015/ https://www.ncbi.nlm.nih.gov/pubmed/28376767 http://dx.doi.org/10.1186/s12883-017-0851-0 |
work_keys_str_mv | AT holmøytrygve highdosevitamindsupplementationdoesnotaffectbiochemicalbonemarkersinmultiplesclerosisarandomizedcontrolledtrial AT lindstrømjonaschristoffer highdosevitamindsupplementationdoesnotaffectbiochemicalbonemarkersinmultiplesclerosisarandomizedcontrolledtrial AT eriksenerikfink highdosevitamindsupplementationdoesnotaffectbiochemicalbonemarkersinmultiplesclerosisarandomizedcontrolledtrial AT steffensenlinnhofsøy highdosevitamindsupplementationdoesnotaffectbiochemicalbonemarkersinmultiplesclerosisarandomizedcontrolledtrial AT kampmanmargittat highdosevitamindsupplementationdoesnotaffectbiochemicalbonemarkersinmultiplesclerosisarandomizedcontrolledtrial |